Skip to main content

Advertisement

SpringerLink
Log in

Diabetes Medications and Bone

  • Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Type 2 diabetes mellitus (T2DM) is a common chronic disease that may be associated with an increased risk of fracture. Evidence that thiazolidinediones (TZDs) increase fracture risk in women with T2DM has focused attention on the skeletal effects of treatments for diabetes. Only scant, low-quality evidence is available for non-TZD diabetes medications and bone health, but it suggests that there are no clinically important effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.

    Article  PubMed  Google Scholar 

  2. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91:3404–10.

    Article  PubMed  CAS  Google Scholar 

  3. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012;27:2231–7.

    Article  PubMed  Google Scholar 

  4. Thrailkill KM, Lumpkin Jr CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol. 2005;289:E735–45.

    Article  CAS  Google Scholar 

  5. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int. 1996;59:492–5.

    Article  PubMed  CAS  Google Scholar 

  6. Dennison EM, Syddall HE, Sayer AA, Craighead S, Phillips DIW, Cooper C. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia. 2004;47:1963–8.

    Article  PubMed  CAS  Google Scholar 

  7. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 1993;265:E655–9.

    PubMed  CAS  Google Scholar 

  8. Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case–control study. Diabetes Care. 2008;31:199–203.

    Article  PubMed  Google Scholar 

  9. Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int. 2006;17:495–500.

    Article  PubMed  Google Scholar 

  10. Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia. 2014;57:2057–65.

    Article  PubMed  CAS  Google Scholar 

  11. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  Google Scholar 

  12. The Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Article  Google Scholar 

  13. Fronczek-Sokol J, Pytlik M. Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats. Pharmacol Rep. 2014;66:412–7.

    Article  PubMed  Google Scholar 

  14. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292–9.

    Article  PubMed  CAS  Google Scholar 

  15. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6:e1000154.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95:134–42.

    Article  PubMed  CAS  Google Scholar 

  17. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes - an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845–51.

    Article  PubMed  CAS  Google Scholar 

  18. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561–73.

    Article  PubMed  CAS  Google Scholar 

  19. Grey AB. Thiazolidinedione-induced skeletal fragility—mechanisms and implications. Diabetes Obes Metab. 2009;11:275–84.

    Article  PubMed  CAS  Google Scholar 

  20. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996;50:1087–94.

    PubMed  CAS  Google Scholar 

  21. Grey AB. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129–37.

    Article  PubMed  CAS  Google Scholar 

  22. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–54.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305–10.

    Article  PubMed  CAS  Google Scholar 

  24. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Tutuncu NB, Demirag NG. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab. 2007;92:3523–30.

    Article  PubMed  CAS  Google Scholar 

  25. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–9.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–35.

    Article  PubMed  CAS  Google Scholar 

  27. Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab. 2009;94:2792–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  28. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115–23. A recent meta-analysis of randomized trial data on the effects of thiazolidinediones on fracture risk and bone mineral density.

    Article  PubMed  CAS  Google Scholar 

  29. Borges JLC, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011;13:1036–46.

    Article  PubMed  CAS  Google Scholar 

  30. Bilezikian JP, Josse RG, Eastell R, et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:1519–28 Recent randomized trials of the effects of thiazolidinediones on bone mineral density and bone turnover in type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  31. Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013;98:4691–701. Recent randomized trials of the effects of thiazolidinediones on bone mineral density and bone turnover in type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  32. Grey A, Bolland MJ, Fenwick S, Horne AM, Gamble GD, Drury PL, et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol. 2014;170:255–62. Recent randomized trials of the effects of thiazolidinediones on bone mineral density and bone turnover in type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  33. Schwartz AV, Vittinghoff E, Margolis KL, Scibora LM, Palermo L, Ambrosius WT, et al. Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia. Calcif Tissue Int. 2013;92:477–86.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  34. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res. 2010;25:211–21.

    Article  PubMed  CAS  Google Scholar 

  35. Jang WG, Kim EJ, Bae I-H, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone. 2011;48:885–93.

    Article  PubMed  CAS  Google Scholar 

  36. Gao Y, Li Y, Xue J, Jia Y, Hu J. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol. 2010;635:231–6.

    Article  PubMed  CAS  Google Scholar 

  37. Tolosa MJ, Chuguransky SR, Sedlinsky C, Schurman L, McCarthy AD, Molinuevo MS, et al. Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin. Diabetes Res Clin Pract. 2013;101:177–86.

    Article  PubMed  CAS  Google Scholar 

  38. Salai M, Somjen D, Gigi R, Yakobson O, Katzburg S, Dolkart O. Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study. Bone Joint J. 2013;95-B:1575–80.

    Article  PubMed  CAS  Google Scholar 

  39. Kasai T, Bandow K, Suzuki H, Chiba N, Kakimoto K, Ohnishi T, et al. Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol. 2009;221:740–9.

    Article  PubMed  CAS  Google Scholar 

  40. Jeyabalan J, Viollet B, Smitham P, Ellis SA, Zaman G, Bardin C, et al. The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int. 2013;24:2659–70.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  41. van Lierop AH, Hamdy NAT, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol. 2012;166:711–6.

    Article  PubMed  CAS  Google Scholar 

  42. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.

    Article  PubMed  CAS  Google Scholar 

  43. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149:574–9.

    Article  PubMed  CAS  Google Scholar 

  44. Xie D, Zhong Q, Ding K-H, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007;40:1352–60.

    Article  PubMed  CAS  Google Scholar 

  45. Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res. 2013;28:1641–52.

    Article  PubMed  CAS  Google Scholar 

  46. Kim J-Y, Lee S-K, Jo K-J, Song D-Y, Lim D-M, Park K-Y, et al. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci. 2013;92:533–40.

    Article  PubMed  CAS  Google Scholar 

  47. Bunck MC, Eliasson B, Corner A, Heine RJ, Shaginian RM, Taskinen MR, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:374–7.

    Article  PubMed  CAS  Google Scholar 

  48. Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes. 2014;6:260–6.

    Article  PubMed  CAS  Google Scholar 

  49. Su B, Sheng H, Zhang M, et al. (2014) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine

  50. Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPARγ activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology. 2011;152:457–67.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  51. Cusick T, Mu J, Pennypacker BL, et al. Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. Diabetes Obes Metab. 2013;15:954–7.

    Article  PubMed  CAS  Google Scholar 

  52. Gallagher EJ, Sun H, Kornhauser C, Tobin-Hess A, Epstein S, Yakar S, et al. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes/Metabol Res Rev. 2014;30:191–200.

    Article  CAS  Google Scholar 

  53. Glorie L, Behets GJ, Baerts L, De Meester I, D’Haese PC, Verhulst A. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Physiol. 2014;307:E447–55.

    CAS  Google Scholar 

  54. Sbaraglini ML, Molinuevo MS, Sedlinsky C, Schurman L, McCarthy AD. Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells. Eur J Pharmacol. 2014;727:8–14.

    Article  PubMed  CAS  Google Scholar 

  55. Bunck MC, Poelma M, Eekhoff EM, Schweizer A, Heine RJ, Nijpels G, et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes. 2012;4:181–5.

    Article  PubMed  CAS  Google Scholar 

  56. Hegazy SK (2014) Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women. J Bone Miner Metab (in press)

  57. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2012;34:2474–6.

    Article  Google Scholar 

  58. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.

    Article  PubMed  CAS  Google Scholar 

  59. Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–9.

    Article  PubMed  CAS  Google Scholar 

  60. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–69.

    Article  PubMed  CAS  Google Scholar 

  61. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

A. Grey declares no conflicts of interest.

Human and Animal Rights and Informed Consent

All studies by A. Grey involving animal and/or human subjects were performed after approval by the appropriate institutional review boards. When required, written informed consent was obtained from all participants.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand

    Andrew Grey

Authors
  1. Andrew Grey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Grey.

Additional information

This article is part of the Topical Collection on Bone and Diabetes

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grey, A. Diabetes Medications and Bone. Curr Osteoporos Rep 13, 35–40 (2015). https://doi.org/10.1007/s11914-014-0250-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-014-0250-z

Keywords

Search

Navigation